Registry for treatment options of localized kidney tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational registry collects data on the management of kidney cancer from 50 high-volume tertiary referral centers worldwide over a two-year period, with a five-year follow-up. It aims to evaluate various treatment approaches, including partial nephrectomy, radical nephrectomy, ablation techniques, and active surveillance, to determine the best personalized strategies for patients with localized renal tumors. The study will utilize a web-based platform for data collection, ensuring comprehensive and standardized information gathering from participating centers.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Radiological diagnosis of renal tumor susceptible to active treatment or AS/WW.
* Age ≥18 years
* Informed consent signed

Exclusion Criteria:

* Patient refuse to participate in clinical research.
* Urothelial renal carcinoma.

Where it's running

• Institute of Urology, University of Southern California.
  Los Angeles, California, United States Recruiting
• University of California San Diego, Moores Cancer Center
  San Diego, California, United States Recruiting
• VCU Health System
  Richmond, Virginia, United States Recruiting
• Medical University of Vienna, Vienna General Hospital
  Vienna, Austria Recruiting
• University of Bruxelles
  Brussels, Belgium Recruiting
• Onze Lieve Vrouw Hospital
  Leuven, Belgium Recruiting

Study contacts

• Principal investigator: Andrea Minervini, Prof. — Dipartimento di Medicina Clinica e Sperimentale Via o Piazza Largo Brambilla 3 - 50134 Firenze (Italy)
• Study coordinator: Marco Carini, Prof.
• Email: carini@unifi.it
• Phone: 055 794 6351

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Your Kidney Cancer Immunotherapy: How You Get It and If Labs Can Be At Home

  This study tests whether people with kidney cancer prefer intravenous or subcutaneous immunotherapy and whether at‑home lab draws plus telehealth visits before treatment are practical.

  Recruiting at 7 sites Phase 4 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07872553

• Perioperative UDCA to Protect Kidney Function in Partial Nephrectomy

  This study tests whether giving ursodeoxycholic acid around surgery can help protect kidney function in adults having partial nephrectomy for kidney tumors.

  Recruiting Phase 2 Jinling Hospital, China · Nanjing, Jiangsu · NCT07672860

• Side Effects and Resource Navigation Program for Cancer Patients

  This program tests whether a navigation service helps adults with kidney, bladder, breast, or lung cancer manage immunotherapy better than usual care.

  Recruiting at 7 sites Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 7 other locations · NCT07646847

• EBNK-001 allogeneic NK cell therapy with low-dose IL-15, with or without pembrolizumab, for advanced solid tumors

  This treatment tests an off-the-shelf NK cell product (EBNK-001) given with low-dose IL-15, either alone or with pembrolizumab, in adults with advanced or metastatic solid tumors who have exhausted standard options.

  Recruiting Phase 1/2 Essen Biotech · Beijing, Beijing Municipality · NCT07410676

• HC-7366 plus nivolumab with or without ipilimumab for advanced clear-cell kidney cancer (SHARK)

  This trial tests whether adding HC-7366 to nivolumab, with or without ipilimumab, can help control advanced clear-cell kidney cancer.

  Recruiting at 2 sites Phase 1 M.D. Anderson Cancer Center · Dallas, Texas and 1 other locations · NCT07401875

• Neoadjuvant HIF-2α inhibitor with or without PD-1 antibody for resectable clear cell kidney cancer

  This trial tests whether casdatifan alone or combined with zimberelimab can shrink tumors in people with resectable clear cell kidney cancer before surgery.

  Recruiting at 2 sites Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts and 2 other locations · NCT07397611

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.